Sage rejects Biogen's $469 million takeover offer, says offer ...
3 days ago · Sage Therapeutics said on Monday that its board has unanimously rejected Biogen’s $469 million offer, stating it "significantly undervalues" the company and does not serve …
Sage rebuffs Biogen's buyout offer, eyes strategic alternatives
3 days ago · After receiving and considering an "unsolicited" buyout offer from partner Biogen, Sage Therapeutics is kicking the tires on a range of strategic options. However, the company's …
Sage Rejects Biogen’s Unsolicited Offer, Will Seek Strategic ...
3 days ago · Following a lawsuit filed last week, Sage has officially rejected Biogen’s unsolicited buyout offer, which valued the embattled biotech at just $469 million.
Biogen and Sage Therapeutics Announce Global Collaboration to …
CAMBRIDGE, Mass., Nov. 27, 2020 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Sage Therapeutics, Inc. (Nasdaq: SAGE) announced that they have executed a global …
Sage seeks injunction after Biogen's unsolicited buyout offer
Jan 21, 2025 · Sage said it's board is reviewing Biogen's buyout offer, but a Mizuho analyst said a deal seems unlikely at the current price.
Sage Sues Partner Biogen After Unsolicited Takeover Offer
Jan 21, 2025 · Sage Therapeutics last week sued partner Biogen just days after receiving an unsolicited buyout offer from the pharma for nearly $470 million, according to reporting by …
Sage Therapeutics Announces Discontinuation of the …
Sage and Biogen will continue to partner on ZURZUVAE® (zuranolone), the first and only FDA-approved oral treatment for women with postpartum depression (PPD) and will continue to …
Sage Therapeutics and Biogen Announce Topline Results from …
CAMBRIDGE Mass. – July 24, 2024 – Sage Therapeutics, Inc. (NASDAQ: Sage) and Biogen Inc. (NASDAQ: BIIB) announced topline results from the Phase 2 KINETIC 2 dose-range study of …
Sage Therapeutics Board of Directors Initiates Review of Strategic ...
Jan 10, 2025 · In addition, Sage announced that its Board has unanimously rejected the unsolicited, nonbinding proposal it received from Biogen Inc. (Nasdaq: BIIB) (“Biogen”) on …
Sage rejects Biogen’s $469m takeover bid
3 days ago · Sage Therapeutics has rejected Biogen ’s $469m takeover offer, with its board of directors unanimously concluding that the bid “significantly undervalues” the company.
- Some results have been removed